Stocks and Investing Stocks and Investing
Wed, March 22, 2023
Tue, March 21, 2023
Mon, March 20, 2023
Sat, March 18, 2023
Fri, March 17, 2023

Judah Frommer Maintained (SRPT) at Hold with Decreased Target to $139 on, Mar 17th, 2023


Published on 2024-10-28 02:19:02 - WOPRAI, Judah Frommer
  Print publication without navigation


Judah Frommer of Credit Suisse, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Hold with Decreased Target from $144 to $139 on, Mar 17th, 2023.

Judah has made no other calls on SRPT in the last 4 months.



There are 9 other peers that have a rating on SRPT. Out of the 9 peers that are also analyzing SRPT, 0 agree with Judah's Rating of Hold.



These are the ratings of the 9 analyists that currently disagree with Judah


  • Hartaj Singh of "Oppenheimer" Maintained at Buy with Decreased Target to $150 on, Thursday, March 9th, 2023
  • Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $206 on, Friday, March 3rd, 2023
  • Brian Skorney of "Baird" Maintained at Buy with Increased Target to $202 on, Wednesday, March 1st, 2023
  • Matthew Harrison of "Morgan Stanley" Upgraded from Hold to Buy and Increased Target to $187 on, Wednesday, March 1st, 2023
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $190 on, Wednesday, March 1st, 2023
  • Gavin Clark-Gartner of "Evercore ISI Group" Maintained at Buy with Increased Target to $171 on, Wednesday, March 1st, 2023
  • Joseph Schwartz of "SVB Leerink" Reiterated at Buy and Held Target at $160 on, Friday, January 20th, 2023
  • Yun Zhong of "BTIG" Maintained at Strong Buy with Increased Target to $160 on, Thursday, December 22nd, 2022
  • Colin Bristow of "UBS" Upgraded from Hold to Strong Buy and Increased Target to $158 on, Friday, December 16th, 2022